{"title":"达格列净在难治性心力衰竭伴射血分数降低的非压实性心肌病中的作用:不稳定障碍的第四大支柱","authors":"Pankaj V. Jariwala , Dilip Gude","doi":"10.1016/j.ihjccr.2022.11.004","DOIUrl":null,"url":null,"abstract":"<div><p>Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown in the <strong><em>Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study</em></strong> to significantly decrease mortality or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF). We describe a case of a patient with noncompaction cardiomyopathy (NCCM) who initially responded partially to guideline-directed medical therapy, which included an angiotensin receptor-neprilysin inhibitor (ARNI). However, the patient's symptoms returned, and the addition of dapagliflozin was able to provide a definitive improvement in his clinical-echocardiographic parameters. There is currently no data indicating that dapagliflozin is beneficial for patients with NCCM and HFrEF which progressive disorder.</p></div>","PeriodicalId":100653,"journal":{"name":"IHJ Cardiovascular Case Reports (CVCR)","volume":"6 4","pages":"Pages 158-162"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468600X22000676/pdfft?md5=05e1725620d2b1c3c90a8adaf2b4cdf4&pid=1-s2.0-S2468600X22000676-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The role of dapagliflozin in non-compaction cardiomyopathy for refractory heart failure with reduced ejection fraction: 4th pillar for unstable disorder\",\"authors\":\"Pankaj V. Jariwala , Dilip Gude\",\"doi\":\"10.1016/j.ihjccr.2022.11.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown in the <strong><em>Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study</em></strong> to significantly decrease mortality or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF). We describe a case of a patient with noncompaction cardiomyopathy (NCCM) who initially responded partially to guideline-directed medical therapy, which included an angiotensin receptor-neprilysin inhibitor (ARNI). However, the patient's symptoms returned, and the addition of dapagliflozin was able to provide a definitive improvement in his clinical-echocardiographic parameters. There is currently no data indicating that dapagliflozin is beneficial for patients with NCCM and HFrEF which progressive disorder.</p></div>\",\"PeriodicalId\":100653,\"journal\":{\"name\":\"IHJ Cardiovascular Case Reports (CVCR)\",\"volume\":\"6 4\",\"pages\":\"Pages 158-162\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2468600X22000676/pdfft?md5=05e1725620d2b1c3c90a8adaf2b4cdf4&pid=1-s2.0-S2468600X22000676-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IHJ Cardiovascular Case Reports (CVCR)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468600X22000676\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IHJ Cardiovascular Case Reports (CVCR)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468600X22000676","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The role of dapagliflozin in non-compaction cardiomyopathy for refractory heart failure with reduced ejection fraction: 4th pillar for unstable disorder
Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study to significantly decrease mortality or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF). We describe a case of a patient with noncompaction cardiomyopathy (NCCM) who initially responded partially to guideline-directed medical therapy, which included an angiotensin receptor-neprilysin inhibitor (ARNI). However, the patient's symptoms returned, and the addition of dapagliflozin was able to provide a definitive improvement in his clinical-echocardiographic parameters. There is currently no data indicating that dapagliflozin is beneficial for patients with NCCM and HFrEF which progressive disorder.